|
Medivation’s executive team boasts experts from pharmaceutical, biotechnology and medical device companies, all of whom have a proven track record in medical product development. As seasoned business people and as clinicians and scientists, they guide Medivation in the acquisition and development of our technologies, bringing them from the laboratory bench to the patient bedside quickly, efficiently and with enhanced value.
David T. Hung, M.D.
President, Chief Executive Officer, Director
C. Patrick Machado, J.D.
Senior Vice President, Chief Financial Officer
Rohan Palekar
Chief Commercial Officer
Lynn Seely, M.D.
Chief Medical Officer
Michele D. Bronson, Ph.D.
Vice President, Regulatory and Quality
Sarvajit Chakravarty, Ph.D.
Vice President, Medicinal Chemistry
Mohammad Hirmand, M.D.
Vice President, Clinical Development
Joyce Mordenti, Ph.D.
Vice President, Translational Medicine
Andrew A. Protter, Ph.D.
Vice President, Preclinical Development
Lisa Taylor
Vice President, Commercial Development
Sue Wollowitz, Ph.D.
Vice President, Chemistry and Manufacturing
David T. Hung, M.D.
President and Chief Executive Officer, Director
Dr. Hung became president and chief executive officer of Medivation, Inc. and a member of the Board of Directors when the Company acquired its subsidiary Medivation Neurology, Inc. in December 2004. He served as president, chief executive officer and director of Medivation Neurology, Inc. since its inception in September 2003. From 1998 to 2001, Dr. Hung served as chief scientific officer (1998-1999) and as president, chief executive officer and director (1999-2001) of ProDuct Health, Inc., a privately-held medical device company. ProDuct Health, Inc. took its first product (a breast cancer cytological diagnostic product) from a prototype design through a 507 patient clinical trial and through FDA marketing clearance in 16 months. It was acquired in 2001 by Cytyc Corporation for $167 million after having spent only approximately $22 million in total development costs. From 1994 to 1998, Dr. Hung served in various senior positions at Chiron Corporation, most recently as vice president of lead discovery and development and vice president of new projects. Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in biology from Harvard College
Top
C. Patrick Machado
Senior Vice President, Chief Financial Officer
Mr. Machado became senior vice president and chief financial officer in December 2004 upon the Company’s acquisition of its subsidiary Medivation Neurology, Inc. Mr. Machado served as senior vice president, chief financial officer and director of Medivation Neurology, Inc. since its inception in September 2003. From 1998 to 2001, he served as vice president, chief financial officer and general counsel (1998-2000) and as senior vice president and chief financial officer (2000-2001) of ProDuct Health, Inc., a privately-held medical device company. From 2001 to 2002, he served as a consultant to Cytyc Corporation to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. From 1996 to 1998, Mr. Machado served as head of business development for new projects (working with Dr. Hung) and in senior business development and legal functions at Chiron Corporation. He received a J.D. cum laude from Harvard Law School and a B.A. and B.S. summa cum laude in German and economics, respectively, from Santa Clara University.
Top
Rohan Palekar
Chief Commercial Officer
Mr. Palekar joined Medivation as chief commercial officer in January 2008, following a 16-year commercial career at the Johnson & Johnson family of companies in positions of increasing seniority. From 2005 to 2008, Mr. Palekar served as vice president, sales and marketing—dermatology for Centocor, Inc., where he led the sales and marketing group for Remicade®, a multi-billion dollar anti-TNF antibody. From 2003 to 2005, Mr. Palekar was worldwide vice president, global biologics strategic marketing for Centocor, where he managed a portfolio of more than ten molecules targeting a broad range of indications. Mr. Palekar also served as a member of the Johnson & Johnson Pharmaceuticals Group Marketing Excellence Steering Committee. Mr. Palekar earned a Bachelor of Commerce and a Bachelor of General Laws from the University of Bombay and a Master of Business Administration from the Amos Tuck School of Business Administration at Dartmouth College.
Top
Lynn Seely, M.D.
Chief Medical Officer
Dr. Seely joined Medivation as chief medical officer in May 2005. From 2002 to 2005, she served as vice president of clinical development at Corgentech, Inc., a biomedical company. She served as vice president of clinical development at ProDuct Health, Inc., a privately-held medical device company, from 2000 to 2001, and subsequently served as vice president of clinical development for Cytyc Health Corporation, a medical device company and subsidiary of Cytyc Corporation, from 2001 to 2002. While there she assisted with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. From 1996 through 2000, she served as an associate director of clinical development at Chiron Corporation. Dr. Seely has led teams running clinical trials in all phases of development in a variety of therapeutic indications. Dr. Seely received an M.D. Alpha Omega Alpha from the University of Oklahoma, College of Medicine and completed her residency and served as chief resident in internal medicine at Yale-New Haven Hospital. She is board-certified in internal medicine and endocrinology and metabolism and was on faculty at the University of California, San Diego prior to joining industry.
Top
Michele D. Bronson, Ph.D.
Vice President, Regulatory and Quality
Dr. Bronson joined Medivation in September 2006 as senior director, regulatory, quality and project management and was promoted to vice president, regulatory and quality in January 2008. Prior to joining Medivation, Dr. Bronson held positions of increasing responsibility in regulatory affairs at Chiron Corporation, including director in the oncology development organization, where she was responsible for approved products and developmental therapeutics. She joined Chiron Corporation from SEQUUS Pharmaceuticals where she was responsible for the development and accelerated approval of DOXIL for the treatment of ovarian cancer. Dr. Bronson began her career in drug development at Cato Research, a contract research organization. She earned a Ph.D. in molecular immunology from the University of Texas Southwestern Medical School and completed a post-doctoral fellowship at the University of California, San Francisco.
Top
Sarvajit Chakravarty, Ph.D.
Vice President, Medicinal Chemistry
Dr. Chakravarty joined Medivation as vice president of medicinal chemistry in July 2007. He has more than 15 years of experience in medicinal chemistry, drug discovery and development in several therapeutic areas, including central nervous system disorders, inflammation and oncology. Previously, he held medicinal chemistry positions of increasing seniority at Scios, Inc., serving most recently as director of medicinal chemistry. While at Scios, he played a significant role in the discovery and development of novel kinase inhibitors. Dr. Chakravarty is an author on more than 30 scientific publications and an inventor on 15 issued patents. He received his B.Sc. in chemistry from St. Stephen’s College, Delhi University in Delhi, India, and his Ph.D. in organic chemistry from New York University.
Top
Mohammad Hirmand, M.D.
Vice President, Clinical Development
Dr. Hirmand joined Medivation as senior director, clinical development in August 2007 and was promoted to vice president, clinical development in February 2008. Before joining the Company, he was a senior director of clinical development at Nuvelo, Inc., where he led the clinical development department comprised of clinical operations, clinical data management and clinical sciences/medical monitor staff. Before that, he served as director of oncology development at SuperGen, Inc. and as associate director of clinical research at Amgen, Inc. (formerly Tularik, Inc.), where he led clinical development efforts for Tularik’s oncology trials. Early in his career, he was a clinical scientist and manager of market development and product evaluation at Theravance, Inc. Dr. Hirmand received his M.D. from Harvard Medical School.
Top
Joyce Mordenti, Ph.D.
Vice President, Translational Medicine
Dr. Mordenti joined Medivation in July 2007 as senior director, translational medicine and was promoted in February 2008 to vice president, translational medicine. Dr. Mordenti has more than 20 years of clinical and preclinical experience at multidisciplinary drug discovery and development organizations. Prior to joining Medivation, she was senior director of drug metabolism and pharmacokinetics for Celera Genomics (formerly Axys). Before that, she held positions of increasing seniority at Genentech, including group leader/senior scientist of experimental therapeutics in the Research Division. Earlier in her career, she served as associate director of the Clinical Drug Studies Unit at the University of California, San Francisco, School of Pharmacy. She received a Ph.D. in pharmaceutical sciences from the University of Connecticut and received training as a clinical fellow at the University of California, San Francisco School of Medicine.
Top
Andrew A. Protter, Ph.D.
Vice President, Preclinical Development
Dr. Protter joined Medivation in September 2006 following a 24-year career at Scios, Inc., where he served most recently as vice president, biology, from 2003 to 2006. At Scios, which was acquired in 2003 by Johnson & Johnson, Dr. Protter had responsibility for all preclinical development activities for Natrecor®, a recombinant protein approved by the FDA in 2001 to treat acute decompensated congestive heart failure, and for multiple small-molecule product candidates. In recognition of his work, Dr. Protter was awarded the 2004 Johnson Medal for Natrecor research and development. Dr. Protter has published extensively in the fields of natriuretic peptides, lipid transport and intracellular kinases regulating inflammation, pain and fibrosis. He received a Ph.D. in biochemistry from the State University of New York, Stony Brook.
Top
Lisa Taylor
Vice President, Commercial Development
Ms. Taylor joined Medivation as vice president, commercial development, in January 2007. She has more than 20 years of medical marketing and strategy experience, including pharmaceuticals, biotechnology, medical devices and in vitro diagnostics. Her expertise includes commercial development assessment, strategic analysis, primary and secondary market research and pre-launch market planning. She joined the Company from Packers Falls Group, Inc., a consultancy she founded and for which she has served as principal for more than a decade. Earlier in her career, she held positions with Natus Medical Inc., Medasonics, Angenics, Inc., Ciba-Corning Diagnostics and Booz, Allen & Hamilton. She holds an A.B. in Human Biology from Stanford University and an M.B.A. from Harvard Business School.
Top
Sue Wollowitz, Ph.D.
Vice President, Chemistry and Manufacturing
Dr. Wollowitz joined Medivation as vice president, chemistry and manufacturing, in December 2006. She has more than 20 years of experience in drug discovery and development. Previously, she served as president of Wollowitz Associates, a consulting business that assists small and emerging pharmaceutical companies in process scale-up, outsourcing, in-licensing and regulatory approvals. Prior to that, she held various senior positions at Cerus Corporation, including vice president of chemical technology and vice president of shared sciences, where she led the discovery and product development of novel compounds for inactivation of pathogens in blood products. Dr. Wollowitz previously worked at Dow Chemical Company and has invented several novel antivirals, one of which is sold commercially in Europe, as well as novel pesticides and polymer additives. Dr. Wollowitz received her B.A. in chemistry from the State University of New York at Binghamton and her Ph.D. in organic chemistry from the University of Wisconsin at Madison.
Top
|
